-
-
-
-
-
-
-
Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
-
-
-
-
-
-
-
Needham Reiterates Hold Rating on ResMed (RMD)
-
-
-
-
-
-
-
ResMed beats estimates on strong sleep apnea device sales
-
-
-
-
-
-
-
ResMed to Report Third Quarter Fiscal 2023 Earnings on April 27, 2023
-
-
-
-
-
-
-
UPDATE: BofA Securities Upgrades ResMed (RMD) to Buy; Sees Q1 'Beat'
-
-
-
-
-
-
-
UPDATE: RBC Capital Upgrades ResMed (RMD) to Outperform
-
-
-
-
-
-
-
UPDATE: CLSA Upgrades ResMed (RMD:AU) (RMD) to Buy (1)
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

